तुलना करने के लिए मीट्रिक्स | 328130 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध328130पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −14.1x | −2.5x | −0.4x | |
PEG अनुपात | −0.63 | 0.04 | 0.00 | |
क़ीमत/बुक | 2.4x | 1.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 8.6x | 2.8x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 13.6% | 50.4% | 47.9% | |
उचित मूल्य अपसाइड | अनलॉक करें | 35.4% | 6.3% | अनलॉक करें |
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.